发明授权
EP1543016B1 NEW 3-DECLADINOSYL DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9A-AZA-9A-HOMOERYTHROMYCIN A 9A,11-CYCLIC CARBAMATES
有权
9-脱氧 - 9-二氢9A-AZA-9A-HOMOERYTHROMICIN甲9A 3- decladinosyl衍生物,11-环状氨基甲酸酯
- 专利标题: NEW 3-DECLADINOSYL DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9A-AZA-9A-HOMOERYTHROMYCIN A 9A,11-CYCLIC CARBAMATES
- 专利标题(中): 9-脱氧 - 9-二氢9A-AZA-9A-HOMOERYTHROMICIN甲9A 3- decladinosyl衍生物,11-环状氨基甲酸酯
-
申请号: EP03769705.9申请日: 2003-09-26
-
公开(公告)号: EP1543016B1公开(公告)日: 2009-04-15
- 发明人: BERDIK, Andrea GlaxoSmithKline istrazivacki centar Zagreb d.o.o. , KOBREHEL, Gabrijela , LAZAREVSKI, Gorjana GlaxoSmithKline istrazivacki centar Zagreb d.o.o. , MUTAK, Stjepan GlaxoSmithKline istrazivacki centar Zagreb d.o.o.
- 申请人: GlaxoSmithKline istrazivacki centar Zagreb d.o.o.
- 申请人地址: Prilaz Baruna Filipovica 29 10000 Zagreb HR
- 专利权人: GlaxoSmithKline istrazivacki centar Zagreb d.o.o.
- 当前专利权人: GlaxoSmithKline istrazivacki centar Zagreb d.o.o.
- 当前专利权人地址: Prilaz Baruna Filipovica 29 10000 Zagreb HR
- 代理机构: von Füner, Nicolai
- 优先权: HR20020779 20020927
- 国际公布: WO2004029067 20040408
- 主分类号: C07H17/08
- IPC分类号: C07H17/08 ; C07H17/00 ; A61K31/7048 ; A61P31/04
摘要:
The present invention relates to the new 3-decladinosyl derivatives of 9-deoxo-9a-aza9a-homoerythromycin A 9a,11-cyclic carbamate of the general formula (I), their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, wherein R1 individually stands for hydrogen, hydroxyl or a group of the formula (II), wherein X individually stands for C1-C6alkyl group, C2-C6alkenyl group or X individually stands for C1-C6alkyl group with at least one incorporated O, S or N atom or X individually stands for (CH2)n-Ar or X individually stands for (CH2)n-heterocycloalkyl, wherein (CH2)n individually stands for alkyl, wherein n is 1-10, with or without incorporated atom O, S or N, wherein Ar individually stands for 5-10-membered monocyclic or bycyclic aromatic ring with 0-3 atom O, S or N, unsubstituted or substituted with 1-3 group, which are selected independently from halogen, OH, OMe, NO2, NH2, amino-C1-C3alkyl or amino-C1-C3dialkyl, CN, SO2NH2, C1-C3alkyl, and heterocycloalkyl stands for unaromatic, partially or completely saturated 3-10-membered monocyclic or bicyclic ring system, which includes 3-8-membered monocyclic or bicyclic ring, which includes 6-membered aromatic or heteroaromatic ring connected with a unaromatic ring with or without incorporated O, S or N atom, unsubstituted or substituted with 1-4 group, which are selected independently from halogen, OH, OMe, NO2, NH2, amino-C1-C3alkyl or amino-Cl-C3dialkyl, CN, SO2NH2, C1-C3alkil, -C(O)-, COOH or R1 together with R2 stands for ketone, R2 individually stands for hydrogen or together with R1 stands for ketone or together with R3 stands for ether, R3 individually stands for hydroxyl, a group of the formula -OX or together with R2 stands for ether, R4 individually stands for hydrogen, C1-C4alkyl group or C2-C4alkenyl group, and R5 individually stands for hydrogen or hydroxyl protected group, to intermediates for synthesis of other macrolide compounds with antibacterial activity, to the proces for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to the process for the preparation of pharmaceutical compositions, as well as the use of pharmaceutical compositions for treating bacterial infections.
公开/授权文献
信息查询